
Oncology NEWS International
- Oncology NEWS International Vol 17 No 8
- Volume 17
- Issue 8
Erbitux gains expanded approval in Europe
Cetuximab (Erbitux) has received broader approval in the European Union as a first-line treatment for metastatic colorectal cancer.
Cetuximab (Erbitux) has received broader approval in the European Union as a first-line treatment for metastatic colorectal cancer. Erbitux can now be used in European patients with EGFR-expressing, KRAS wild-type metastatic colorectal cancer in combination with chemotherapy and also as a single agent in patients who have failed oxaliplatin (Eloxatin)-based and irinotecan (Camptosar)-based therapy, according to manufacturer Merck KGaA of Darmstadt, Germany.
European Commission approval was based on data from two randomized, controlled trials. In the phase III CRYSTAL study, patients with KRAS wild-type tumors had a 59% response rate with cetuximab/chemotherapy vs 43% for chemotherapy alone. In the phase II OPUS trial, response rates were 61% vs 37%, respectively.
Articles in this issue
almost 18 years ago
An editor says farewellalmost 18 years ago
High cost of biologics takes a toll on hem/onc practicesalmost 18 years ago
FDA mandates changes to ESA labeling infoalmost 18 years ago
Poll results: Medical education falters on pain reliefalmost 18 years ago
Certification offered to rad oncs for care of dying patientsalmost 18 years ago
VA enlists ACR for RT accreditations; H&N date changealmost 18 years ago
Docs deserve pay for cognitive skill setalmost 18 years ago
Creator of Herceptin goes Hollywood in TV biopicalmost 18 years ago
Avastin/sunitnib RCC trial closes after serious toxicitiesalmost 18 years ago
FDA cracks down on counterfeit cancer cure productsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.

















































